Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola
批准号:
10374719
负责人:
Robert F Garry
金额:
$42.5万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-01 至 2023-01-31
关键词:
AchievementAffectAfricaAfricanAntibodiesAreaBasic ScienceCessation of lifeClinicalClinical ResearchCollaborationsComplementComputational BiologyComputer ModelsData SetDevelopmentDiseaseDisease OutbreaksDisease OutcomeEbolaEbola Hemorrhagic FeverEbola virusEpidemicEuropeEvolutionExposure toGenomicsGeographyGoalsGovernmentHLA AntigensHospital AdministrationHospitalsHourHumanImmunologyIncidenceIndividualInfectionIntegration Host FactorsLassa FeverLassa virusMachine LearningMetabolicMethodsMolecularNigeriaNorth AmericaOutcomePatient-Focused OutcomesPatientsPhysiologicalPopulationProteomicsProvincePublic HealthResearchRodentRoleSamplingSierra LeoneStatistical MethodsStatistical ModelsStructureSurvivorsSystemSystems BiologyT-LymphocyteTestingTherapeuticTimeVaccinesViralViral Hemorrhagic FeversVirusVirus Diseasescohortexperienceimprovedinfection managementmembermultidisciplinarynovelpredictive modelingpredictive testpreventprogramsrole modelvirologyweapons
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary / Abstract
The Eastern Province of Sierra Leone has the world’s highest incidence of Lassa fever. Members of this
research team have been working on Lassa fever at the Kenema Government Hospital (KGH) for over twelve
years. The 2013-16 West African Ebola epidemic began less than a four-hour drive from KGH and was the
first Ebola outbreak to occur in an area close to an existing facility for viral hemorrhagic fever basic and
clinical research. KGH manages up to 600 suspected Lassa fever patients per year, and Kenema and
surrounding districts experienced a large number of Ebola case. We will leverage existing samples from these
established cohorts of humans infected with Lassa fever or Ebola. While it is well established that
asymptomatic or mildly symptomatic infections occur in both Lassa fever and Ebola, it is unknown which host
factors determine the progression to fulminant hemorrhagic fever. Likewise, a substantial portion of Lassa
fever and Ebola survivors develop a plethora of serious sequelae, but factors that predicate these
complications remain elusive. Our research program supports both Lassa fever and Ebola survivor groups.
We propose to integrate experimental approaches and computational modeling to test and validate
hypotheses of significance to Lassa fever and Ebola. Our assembled team has a track record of collaboration,
unique expertise with both Lassa virus and Ebola virus and the appropriate multidisciplinary representation in
systems and computational biology, virology, immunology, genomics, proteomics, machine learning,
statistical methods and modeling required to execute the proposed program. Our overall goal in Project 1 is to
generate an integrated dataset that can be used to build predictive models of patient outcomes in Lassa fever
and Ebola. Studies proposed under Specific Aim 1 will define physiological attributes that distinguish Lassa
fever and Ebola survivors and non-survivors, and individuals that develop serious sequelae. Specific Aim 2
will elucidate the evolution and function of successful antibody networks in Ebola and Lassa fever survivors. T
cell dynamics and the role human leukocyte antigens leading to successful clearance of Ebola virus and
Lassa virus will be defined in studies described in Specific Aim 3. In Specific Aim 4 we will develop and test
predictive models for the role of host factors in Lassa fever and Ebola outcome. Project 1 on host factors
complements the studies described in Project 2 on viral factors and integrates with and utilizes each of the
Cores.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails
-
批准号:10158449
-
项目类别:
-
资助金额:$183.19万
-
财政年份:2019
-
负责人:Robert F Garry
-
依托单位:
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails
-
批准号:10402339
-
项目类别:
-
资助金额:$165.87万
-
财政年份:2019
-
负责人:Robert F Garry
-
依托单位:
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails
-
批准号:10617738
-
项目类别:
-
资助金额:$165.87万
-
财政年份:2019
-
负责人:Robert F Garry
-
依托单位:
Project 1
-
批准号:10558423
-
项目类别:
-
资助金额:$88.45万
-
财政年份:2018
-
负责人:Robert F Garry
-
依托单位:
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola
-
批准号:10310605
-
项目类别:
-
资助金额:$10.54万
-
财政年份:2018
-
负责人:Robert F Garry
-
依托单位:
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola
-
批准号:10579086
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:Robert F Garry
-
依托单位:
Structure-based design of novel Lassa virus glycoproteins for vaccine development
-
批准号:10202410
-
项目类别:
-
资助金额:$117.29万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail
-
批准号:9926211
-
项目类别:
-
资助金额:$110.85万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail
-
批准号:10176382
-
项目类别:
-
资助金额:$112.42万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
Structure-based design of novel Lassa virus glycoproteins for vaccine development
-
批准号:10438220
-
项目类别:
-
资助金额:$14.37万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
Structure-based design of novel Lassa virus glycoproteins for vaccine development
-
批准号:10356645
-
项目类别:
-
资助金额:$3.62万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
International Collaboration in Infectious Disease Research on Lassa fever
-
批准号:9012762
-
项目类别:
-
资助金额:$77.03万
-
财政年份:2015
-
负责人:Robert F Garry
-
依托单位:
Antibody immunotherapeutics for biodefense against Lassa virus
-
批准号:8793681
-
项目类别:
-
资助金额:$101.0万
-
财政年份:2013
-
负责人:Robert F Garry
-
依托单位:
Antibody immunotherapeutics for biodefense against Lassa virus
-
批准号:8474396
-
项目类别:
-
资助金额:$133.77万
-
财政年份:2013
-
负责人:Robert F Garry
-
依托单位:
Opening a New Lassa Fever Ward in Kenema Sierra Leone
-
批准号:8459184
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2013
-
负责人:Robert F Garry
-
依托单位:
Antibody immunotherapeutics for biodefense against Lassa virus
-
批准号:9211282
-
项目类别:
-
资助金额:$114.85万
-
财政年份:2013
-
负责人:Robert F Garry
-
依托单位:
Preclinical development of recombinant antigen diagnostics for Lassa fever
-
批准号:8248226
-
项目类别:
-
资助金额:$131.61万
-
财政年份:2009
-
负责人:Robert F Garry
-
依托单位:
Preclinical development of recombinant antigen diagnostics for Lassa fever
-
批准号:8055356
-
项目类别:
-
资助金额:$133.54万
-
财政年份:2009
-
负责人:Robert F Garry
-
依托单位:
Preclinical development of recombinant antigen diagnostics for Lassa fever
-
批准号:8458569
-
项目类别:
-
资助金额:$123.72万
-
财政年份:2009
-
负责人:Robert F Garry
-
依托单位:
Preclinical development of recombinant antigen diagnostics for Lassa fever
-
批准号:7645356
-
项目类别:
-
资助金额:$149.96万
-
财政年份:2009
-
负责人:Robert F Garry
-
依托单位:
海外基金